Featured Products
more+
-
Dicobalt octacarbonylCAS：10210-68-1Molecular Formula：Co2(CO)8 -
2,3,4-TrihydroxybenzaldehydeCAS：2144-08-3Molecular Formula：C7H6O4 -
Guanidine hydrochlorideCAS：50-01-1Molecular Formula：CH5N3.HCl -
DL-Serinohydrazide monohydrochlorideCAS：55819-71-1Molecular Formula：C3H9N3O2.ClH -
2,4,6-Tri(2,4-dihydroxyphenyl)-1,3,5-triazineCAS：2125-23-7Molecular Formula：C21H15N3O6 -
2,3-Dimethyl-6-amino-2H-indazoleCAS：444731-72-0Molecular Formula：C9H11N3 -
S-ETHYLISOTHIOUREA HYDROBROMIDECAS：1071-37-0Molecular Formula： -
1,3,5-Triazine-2,4(1H,3H)-dione, 3-(1,1-dimethylethyl)-6-(ethylthio)-CAS：1360105-53-8Molecular Formula：
New Arrivals
more+
-
2,2-Dimethylpropylamine hydrochlorideCAS：15925-18-5Molecular Formula：C5H13N.HCl -
(1R,3S,5R)-2-(tert-butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acidCAS：1306734-44-0Molecular Formula：C12H19NO4 -
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acidCAS：641569-94-0Molecular Formula：C17H14N4O2 -
2-hydroxy-4-tetradecyl-1,3,2-dioxaborolaneCAS：84819-41-0Molecular Formula：C16H33BO3 -
(3,3-Difluoro-1-Methyl-cyclobutyl)MethanolCAS：1408076-35-6Molecular Formula：C6H10F2O -
3-(Trifluoromethyl)benzaldehydeCAS：454-89-7Molecular Formula：C8H5F3O -
5-Aminoisophthalic acidCAS：99-31-0Molecular Formula：C8H7NO4 -
(trans,trans)-4-(1E)-1-Propen-1-yl-4'-propyl-1,1'-bicyclohexylCAS：279246-65-0Molecular Formula：C18H32
Contact us
Email:：[email protected]
News
more+
-
11-26Allegro Ophthalmics Announces Positive Results of Vehicle-controlled Ex-U.S. Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye DiseaseAllegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel oxidative stress stabilizers for the treatment of ocular diseases, today announced that all primary and secondary endpoints of an ex-U.S. vehicle-cont
-
11-15Janssen Licenses "Flexible Antibody" Technology from F-star in New CollabClinical-stage biopharma company F-star Therapeutics announced a new partnership with Janssen Biotech on Wednesday, only one month after presenting an optimistic trial-in-progress update to the public on its tetravalent dual T-cell agonist FS120 at the Eu
-
11-09Palleon to Present Preclinical Data on Lead Immuno-Oncology Program, E-602, at SITC Annual MeetingWALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced it will present new preclinical data on the company’s lead immuno-oncology program, E
Technical FAQ
more+
Services
Notice